<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45320">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516306</url>
  </required_header>
  <id_info>
    <org_study_id>EV-C-002</org_study_id>
    <nct_id>NCT02516306</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia</brief_title>
  <official_title>A Phase 1/2 Prospective, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution (Lipoic Acid Choline Ester, 1.5%), in Improving Distance Corrected Near Vision in Subjects With Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Encore Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Encore Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether EV06 is safe and effective in improving
      distance-corrected near vision in people who have presbyopia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance Corrected Near Visual Acuity (DCNVA)</measure>
    <time_frame>90 days</time_frame>
    <description>Is there a change in the DCNVA score?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Distance Visual Acuity (BCDVA)</measure>
    <time_frame>90 days</time_frame>
    <description>Is there a change in the BCDVA score?</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Slit lamp findings</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline in Slit Lamp examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Fundus findings</measure>
    <time_frame>90 days</time_frame>
    <description>Change from baseline in Fundus examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>90 days</time_frame>
    <description>Is there a change in the intraocular pressure?</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective accommodative amplitude by defocus curves</measure>
    <time_frame>90 days</time_frame>
    <description>Is there a change in the subjective accommodative amplitude by defocus curves?</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>EVO6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle minus EV06</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EV06 (Lipoic Acid Choline Ester, 1.5%)</intervention_name>
    <description>A 1.5% topical ophthalmic solution administered twice a day intended to treat presbyopia by reversing age-related changes in the crystalline lens that result in diminished lens elasticity.</description>
    <arm_group_label>EVO6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A topical ophthalmic solution administered twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle minus EVO6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  45 to 55 years of age

          -  DCNVA worse than 20/40

          -  BCDVA of 20/20 or better in each eye

          -  Willing and able to sign consent, following study instructions

        Exclusion Criteria:

          -  Certain pupillary conditions

          -  Significant astigmatism, glaucoma, diabetes, cataracts, eye surgery, ocular trauma or
             accommodative issues

          -  contact lens wear within 3 days prior to and for duration of study

          -  use of prohibited medications

          -  participation in a clinical study within 30 days prior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sall Research Medical Center, Inc.</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care, Ltd.</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 8, 2016</lastchanged_date>
  <firstreceived_date>July 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia, Vision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Choline</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
